PMID- 37642226
OWN - NLM
STAT- MEDLINE
DCOM- 20240131
LR  - 20240131
IS  - 1873-5576 (Electronic)
IS  - 1568-0096 (Linking)
VI  - 24
IP  - 2
DP  - 2024
TI  - A Comprehensive Review on Current Treatments and Challenges Involved in the 
      Treatment of Ovarian Cancer.
PG  - 142-166
LID - 10.2174/1568009623666230811093139 [doi]
AB  - Ovarian cancer (OC) is the second most common gynaecological malignancy. It 
      typically affects females over the age of 50, and since 75% of cases are only 
      discovered at stage III or IV, this is a sign of a poor diagnosis. Despite 
      intraperitoneal chemotherapy's chemosensitivity, most patients relapse and face 
      death. Early detection is difficult, but treatment is also difficult due to the 
      route of administration, resistance to therapy with recurrence, and the need for 
      precise cancer targeting to minimize cytotoxicity and adverse effects. On the 
      other hand, undergoing debulking surgery becomes challenging, and therapy with 
      many chemotherapeutic medications has manifested resistance, a condition known as 
      multidrug resistance (MDR). Although there are other therapeutic options for 
      ovarian cancer, this article solely focuses on co-delivery techniques, which work 
      via diverse pathways to overcome cancer cell resistance. Different pathways 
      contribute to MDR development in ovarian cancer; however, usually, pump and 
      non-pump mechanisms are involved. Striking cancerous cells from several angles is 
      important to defeat MDR. Nanocarriers are known to bypass the drug efflux pump 
      found on cellular membranes to hit the pump mechanism. Nanocarriers aid in the 
      treatment of ovarian cancer by enhancing the delivery of chemotherapeutic drugs 
      to the tumour sites through passive or active targeting, thereby reducing 
      unfavorable side effects on the healthy tissues. Additionally, the enhanced 
      permeability and retention (EPR) mechanism boosts the bioavailability of the 
      tumour site. To address the shortcomings of conventional delivery, the current 
      review attempts to explain the current conventional treatment with special 
      reference to passively and actively targeted drug delivery systems (DDSs) towards 
      specific receptors developed to treat ovarian cancer. In conclusion, tailored 
      nanocarriers would optimize medication delivery into the intracellular 
      compartment before optimizing intra-tumour distribution. Other novel treatment 
      possibilities for ovarian cancer include tumour vaccines, gene therapy, targeting 
      epigenetic alteration, and biologically targeted compounds. These characteristics 
      might enhance the therapeutic efficacy.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Saman, Saika
AU  - Saman S
AD  - Department of Pharmaceutics, Faculty of Pharmacy, Amity Institute of Pharmacy, 
      Lucknow, Amity University Uttar Pradesh, Sector 125, Noida, 201313, India.
FAU - Srivastava, Nimisha
AU  - Srivastava N
AUID- ORCID: 0000-0002-6566-6335
AD  - Department of Pharmaceutics, Faculty of Pharmacy, Amity Institute of Pharmacy, 
      Lucknow, Amity University Uttar Pradesh, Sector 125, Noida, 201313, India.
FAU - Yasir, Mohd
AU  - Yasir M
AD  - Department of Pharmacy (Pharmaceutics), College of Health Sciences, Arsi 
      University, Asella, Ethiopia.
FAU - Chauhan, Iti
AU  - Chauhan I
AD  - Department of Pharmacy, I.T.S College of Pharmacy, Muradnagar, Ghaziabad, India.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Cancer Drug Targets
JT  - Current cancer drug targets
JID - 101094211
SB  - IM
MH  - Humans
MH  - Female
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - *Ovarian Neoplasms/drug therapy/pathology
MH  - Drug Delivery Systems/methods
MH  - Drug Resistance, Multiple
MH  - *Nanoparticles
OTO - NOTNLM
OT  - Ovaries
OT  - chemotherapy
OT  - multidrug resistance
OT  - nano-systems.
OT  - nanocarriers
OT  - ovarian cancer
EDAT- 2023/08/29 12:42
MHDA- 2024/01/31 06:42
CRDT- 2023/08/29 07:23
PHST- 2023/01/20 00:00 [received]
PHST- 2023/03/13 00:00 [revised]
PHST- 2023/03/31 00:00 [accepted]
PHST- 2024/01/31 06:42 [medline]
PHST- 2023/08/29 12:42 [pubmed]
PHST- 2023/08/29 07:23 [entrez]
AID - CCDT-EPUB-133554 [pii]
AID - 10.2174/1568009623666230811093139 [doi]
PST - ppublish
SO  - Curr Cancer Drug Targets. 2024;24(2):142-166. doi: 
      10.2174/1568009623666230811093139.